Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition of medication for treating cardiovascular diseases and cerebrovascular diseases

A technology for cardiovascular and cerebrovascular diseases and compositions, which can be applied to cardiovascular system diseases, drug combinations, drug delivery, etc., and can solve problems such as reducing and increasing cerebral blood flow, and large and unsafe drug dosages

Inactive Publication Date: 2007-12-26
GUIZHOU XINBANG YUANDONG PHARMACEUTICAL CO LTD
View PDF0 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The purpose of the present invention is to combine two drugs that act on different targets and can significantly reduce the infarct area of ​​the brain tissue and significantly reduce the behavioral disorder caused by brain tissue necrosis. Since the drug interaction is a synergistic interaction, And it is stronger than the additive effect of individual drugs; it solves the problem of unsafe drug dosage; it makes the drug curative effect faster and stronger
The purpose of the present invention is to address the above-mentioned deficiencies in the prior art, and to provide a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular diseases, mainly in order to solve the problem of using ginsenoside Rd or scutellarin alone as the treatment of cardiovascular and cerebrovascular diseases. various issues, will specific receptors manipulate Ca 2+ Channel blocker ginsenoside Rd combined with scutellarin that inhibits protein kinase to increase cerebral blood flow and reduce neutrophil adhesion and infiltration in ischemic brain tissue

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] The preparation of embodiment 1 injection

[0056] 1. Prescription:

[0057] Ginsenoside-Rd 8g

[0058] Scutellarin 8g

[0059] Sodium chloride 9g

[0060] 1,2-propanediol 100ml

[0061] Water for injection about 900ml

[0062]

[0063] Makes 1000ml

[0064] 2. Preparation:

[0065] Take ginsenoside-Rd, scutellarin, sodium chloride, and 1,2-propylene glycol; dissolve sodium chloride to 500ml of 20% propylene glycol aqueous solution, add ginsenoside-Rd and scutellarin, and place on a water bath at 60-70°C Stir until completely dissolved, cool to room temperature, add the remaining amount of water for injection to 1000ml, mix well and filter with a 0.22μm filter membrane. The filtrate is filled in separate bottles, sealed, and sterilized to obtain the product.

Embodiment 2

[0066] The preparation of embodiment 2 dropping pills

[0067] 1. Prescription:

[0068] Ginsenoside Rd 18g

[0069] Scutellarin 2g

[0070] Macrogol 6000 37g

[0071]

[0072] Makes 1000 capsules

[0073] 2. Preparation:

[0074] Take polyethylene glycol 6000, put it in a container, heat it to 70-80°C, wait until it is completely melted, and when the temperature drops to about 50°C, add ginsenoside Rd and scutellarin to melt, and control the temperature at 40-50°C , pour it into a dripping pill machine for dripping, drop into simethicone oil, and make a dripping pill, that is to say.

Embodiment 3

[0075] The preparation of embodiment 3 sublingual lozenge

[0076] 1. Prescription:

[0077] Ginsenoside Rd 10g

[0078] Scutellarin 4g

[0079] Hydroxypropyl methylcellulose (E-50) 80g

[0080] Hydroxypropyl methylcellulose (E-4M) 50g

[0081] Hydroxypropyl Cellulose 20g

[0082] Micronized silica gel 3g

[0083] Magnesium Stearate 7g

[0084]

[0085]Makes 1000 pieces

[0086] 2. Take ginsenoside Rd, scutellarin, hydroxypropyl methylcellulose (E-50), hydroxypropyl methylcellulose (E-4M), hydroxypropyl cellulose, micronized silica gel, stearic acid Magnesium is mixed uniformly by the method of increasing in equal amounts, and directly pressed into sublingual lozenges, that is, it is obtained.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a medicine composition for curing angiocardiopathy and cerebrovascular disease. Said medicine composition contains ginsenoside and breviscapine.

Description

Technical field: [0001] The invention relates to a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, belonging to the technical field of medicines. Background technique: [0002] Cerebrovascular disease has the characteristics of high morbidity, disability, mortality and recurrence, and is one of the biggest killers threatening human health. According to epidemiological surveys, the incidence of cerebrovascular diseases worldwide is 1.4-200 / 100,000 population, and the average death rate is 100 / 100,000 population. With the aggravation of population aging, cerebrovascular disease, especially ischemic cerebrovascular disease has increasingly become one of the major diseases that threaten human health. It has brought a heavy burden and has attracted widespread attention from all countries in the world. The mortality rate of cerebrovascular disease in my country has jumped to the top of various diseases. And in cerebrovascular diseases, ische...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61K9/00A61P9/10A61P9/12A61P25/16A61P25/28A61K31/704
Inventor 张观福杜健
Owner GUIZHOU XINBANG YUANDONG PHARMACEUTICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com